Suppr超能文献

口服崩解型奥氮平与治疗中出现体重增加的潜在差异。

Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.

作者信息

Karagianis Jamie, Hoffmann Vicki Poole, Arranz Belen, Treuer Tamás, Maguire Gerald A, de Haan Lieuwe, Chawla Bharat

机构信息

Clinical Research, Eli Lilly Canada Inc., Toronto, Ontario, Canada.

出版信息

Hum Psychopharmacol. 2008 Jun;23(4):275-81. doi: 10.1002/hup.933.

Abstract

Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine.

摘要

与标准口服奥氮平片相比,有几篇论文和交流报道称,患者开始服用或换用口腔崩解片奥氮平时可能会减轻体重或体重增加较少。本文回顾了当前的文献并讨论了推测的作用机制。数据仍属初步,作用机制尚未完全了解。需要进行随机对照试验以进一步评估口腔崩解片奥氮平治疗期间的体重变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验